Abstract:Background: Over-expression of vascular endothelial growth factor receptors (VEGFRs) leads to the hyperactivation of oncogenes. For inhibition of this hyperactivation, the USA Food Drug Administration (FDA) has approved many drugs that show adverse effects, such as hypertension, hypothyroidism, etc. There is a need to discover potent natural compounds that show minimal side effects. In the present study, we have taken structurally diverse known VEGFR2 inhibitors to develop a quantitative structure-activity relationship (QSAR) model and used this model to predict the inhibitory activity of natural compounds for VEGFR2. background: Over-expression of Vascular Endothelial Growth Factor Receptors (VEGFRs) leads to the hyper activation of oncogenes. For inhibition of this hyper activation, FDA has approved many drugs which show adverse effects such as hypertension, hypothyroid, fatigue, etc. There is a need to discover potent novel natural compounds that show minimal side effects. In the present study, we have taken structurally diverse known VEGFR2 inhibitors to prepare a QSAR model and used this model to predict inhibitory activity of natural compounds for VEGFR2. Methods: The QSAR model was developed through the forward stepwise multiple linear regression (MLR) method. A developed QSAR model was used to predict the inhibitory activity of natural compounds. Absorption, distribution, metabolism, excretion, and toxicity (ADMET) assessment and molecular docking studies were performed. The binding stability of the natural compounds with VEGFR2 was elucidated through molecular dynamics (MD) simulation. objective: Structure-Activity Relationship Studies on VEGFR2 Tyrosine Kinase Inhibitors for Identification of Potential Natural Anticancer Compounds Results: The developed QSAR model against VEGFR2 showed the regression coefficient of the training dataset (r2) to be 0.81 and the external regression coefficient of the test dataset (r2 pred) to be 0.71. Descriptors, viz., electro-topological state of potential hydrogen bonds (maxHBint2, nHBint6), atom types (minssNH), maximum topological distance matrix (SpMAD_Dt), and 2D autocorrelation (ATSC7v), have been identified. Using this model, 14 natural compounds have been selected that have shown inhibitory activity for VEGFR2, of which six natural compounds have been found to possess a strong binding affinity with VEGFR2. In MD simulation, four complexes have shown binding stability up to 10ns. Conclusion: The developed QSAR model has identified 5 conserved activity-inducing physiochemical properties, which have been found to be correlated with the anticancer activity of the nonidentical ligand molecules bound with the VEGFR2 kinase. Lavendustin_A, 3’-O-acetylhamaudol, and arctigenin have been obtained as possible lead natural compounds against the VEGFR2 kinase.

In-silico identification of Coumarin-based natural compounds as potential VEGFR-2 inhibitors

Identification of Novel Potential VEGFR-2 Inhibitors Using a Combination of Computational Methods for Drug Discovery

Quantitative structure activity relationship and molecular simulations for the exploration of natural potent VEGFR-2 inhibitors: an in silico anti-angiogenic study

In Silico Screening of 1,3,4-Thiadiazole Derivatives as Inhibitors of Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2)

Discovery of new potential CDK2/VEGFR2 type II inhibitors by fragmentation and virtual screening of natural products

New Application of Novel Tetrazine Derivatives As Potent VEGFR-2 Kinase Inhibitors and Anti-Cancer Agents

In-silico identification and exploration of small molecule coumarin-1,2,3-triazole hybrids as potential EGFR inhibitors for targeting lung cancer

Discovery of VEGFR2 inhibitors by integrating naïve Bayesian classification, molecular docking and drug screening approaches

Structure-activity Relationship Studies on VEGFR2 Tyrosine Kinase Inhibitors for Identification of Potential Natural Anticancer Compounds

Molecular docking aided machine learning for the identification of potential VEGFR inhibitors against renal cell carcinoma

Identification of plant-based hexokinase 2 inhibitors: combined molecular docking and dynamics simulation studies

In Silico Repurposing of a Novel Inhibitor (drug) of EGFR and VEGFR-2 Kinases of Cancer by Pharmacokinetics, Toxicity, Molecular Docking, and Molecular Dynamics Simulation

Receptor-based pharmacophore modeling, molecular docking, synthesis and biological evaluation of novel VEGFR-2, FGFR-1, and BRAF multi-kinase inhibitors

Design, synthesis, and in silico insights of novel N'-(2-oxoindolin-3-ylidene)piperidine-4-carbohydrazide derivatives as VEGFR-2 inhibitors

Design, synthesis and biological evaluation of quinoline amide derivatives as novel VEGFR-2 inhibitors.

3D-QSAR and Molecular Docking Approaches for the Identification of Novel Phyto-inhibitors of the Cyclin-dependent Kinase 4

Identification of novel c-Kit inhibitors from natural sources using virtual screening and molecular dynamics simulations

In Silico Anticancer Evaluation, Molecular Docking and Pharmacophore Modeling of Flavonoids against Various Cancer Targets

Antiangiogenic potential of phytochemicals from Clerodendrum inerme (L.) Gaertn investigated through in silico and quantum computational methods

1,2,4-Triazole-Tethered Indolinones as New Cancer-Fighting Small Molecules Targeting VEGFR-2: Synthesis, Biological Evaluations and Molecular Docking

Synthesis, Molecular Modeling and Biological Evaluation of 4-Alkoxyquinazoline Derivatives As Novel Inhibitors of VEGFR2.